Voyager Therapeutics Cash on Hand 2014-2022 | VYGR
Voyager Therapeutics cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Voyager Therapeutics Annual Cash on Hand
(Millions of US $) |
| 2021 |
$133 |
| 2020 |
$181 |
| 2019 |
$282 |
| 2018 |
$156 |
| 2017 |
$169 |
| 2016 |
$174 |
| 2015 |
$194 |
| 2014 |
$7 |
| 2013 |
$0 |
Voyager Therapeutics Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$167 |
| 2021-12-31 |
$133 |
| 2021-09-30 |
$121 |
| 2021-06-30 |
$143 |
| 2021-03-31 |
$162 |
| 2020-12-31 |
$181 |
| 2020-09-30 |
$200 |
| 2020-06-30 |
$230 |
| 2020-03-31 |
$251 |
| 2019-12-31 |
$282 |
| 2019-09-30 |
$307 |
| 2019-06-30 |
$327 |
| 2019-03-31 |
$358 |
| 2018-12-31 |
$156 |
| 2018-09-30 |
$180 |
| 2018-06-30 |
$196 |
| 2018-03-31 |
$218 |
| 2017-12-31 |
$169 |
| 2017-09-30 |
$126 |
| 2017-06-30 |
$141 |
| 2017-03-31 |
$158 |
| 2016-12-31 |
$174 |
| 2016-09-30 |
$191 |
| 2016-06-30 |
$204 |
| 2016-03-31 |
$204 |
| 2015-12-31 |
$194 |
| 2015-09-30 |
$108 |
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
$7 |
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.233B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
